Physicians should also discuss the increased risk of NAION with patients who have already experienced NAION in one eye, including whether such individuals could be adversely affected by use of vasodilators, such
as PDE-5 inhibitors.There are no controlled clinical data on the safety or efficacy of Sildenafil for
Sildenafil for Oral Suspension is contraindicated in patients with: Concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension [see Warnings and Precautions (5.2)]. PDE-5 inhibitors, including sildenafil, may potentiate the hypotensive effects of riociguat. 5 WARNINGS AND PRECAUTIONS 5.1 Mortality with Pediatric UseIn a long-term trial in pediatric patients with PAH, an increase in mortality with increasing Sildenafil for Oral Suspension dose was observed. Deaths were first observed after about 1 year and causes of death were typical of patients with PAH. Use of Sildenafil for Oral Suspension, particularly chronic use, is not recommended in children [see Use in Specific Populations (8.4)].5.2 HypotensionSildenafil has vasodilatory properties, resulting in mild and transient decreases in blood pressure.
Before prescribing Sildenafil for Oral Suspension, carefully consider whether patients with certain underlying conditions could be adversely affected by such vasodilatory effects (e.g., patients on antihypertensive therapy or with resting hypotension [BP less than 90/50], fluid depletion, severe left ventricular outflow obstruction, or autonomic dysfunction). Monitor blood pressure when co-administering blood pressure lowering drugs with Sildenafil for Oral Suspension.5.3 Worsening Pulmonary Vascular Occlusive DiseasePulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Since there are no clinical data on administration of Sildenafil for Oral Suspension to patients with veno-occlusive disease, administration of Sildenafil for Oral Suspension to such patients is not recommended. Should signs of pulmonary edema occur when Sildenafil for Oral Suspension is administered, consider the possibility of associated PVOD.5.4 EpistaxisThe incidence of epistaxis was 13% in patients taking Sildenafil with PAH secondary to CTD. The incidence of epistaxis was also higher in Sildenafil for Oral Suspension-treated patients with a concomitant oral vitamin K antagonist (9% versus 2% in those not treated with concomitant vitamin K antagonist).The safety of Sildenafil for Oral Suspension is unknown in patients with bleeding disorders or active peptic ulceration.5.5 Visual LossWhen used to treat erectile dysfunction, non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE-5) inhibitors, including sildenafil. Oral Suspension in patients with retinitis pigmentosa, a minority whom have genetic disorders of retinal phosphodiesterases.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Viagra Generic | 50mg | 270 + 8 Pills | 198.48€ 189.03€ | |
| Kamagra | 100mg | 20 Pills | 86.09€ 81.99€ | |
| Viagra Generic | 25mg | 20 Pills | 37.74€ 35.94€ | |
| Viagra Generic | 100mg | 90 + 6 Pills | 129.02€ 122.88€ | |
| Viagra Generic | 200mg | 120 + 8 Pills | 204.80€ 195.05€ | |
| Kamagra Polo | 100mg | 272 + 12 Pills | 622.94€ 593.28€ | |
| Kamagra Polo | 100mg | 84 + 4 Pills | 244.49€ 232.85€ | |
| Viagra Generic | 200mg | 180 + 10 Pills | 277.56€ 264.34€ | |
| Kamagra Soft Tabs | 100mg | 32 Pills | 120.11€ 114.39€ | |
| Viagra Generic | 150mg | 360 + 10 Pills | 423.48€ 403.31€ | |
| Viagra Generic | 200mg | 360 + 10 Pills | 481.98€ 459.03€ | |
| Kamagra Oral Jelly | 100mg | 10 Sachets | 54.55€ 51.95€ | |
| Viagra Generic | 25mg | 360 + 10 Pills | 213.68€ 203.50€ | |
| Kamagra | 100mg | 360 + 6 Pills | 839.95€ 799.95€ |
Prescribe Sildenafil for Oral Suspension with caution in these patients.5.6 Hearing LossCases of sudden decrease or loss of hearing, which
may be accompanied by tinnitus and dizziness, have been reported in temporal association with the use of PDE-5 inhibitors, including Sildenafil. It is not possible to determine whether these reported events are related directly to the use of Sildenafil
for Oral Suspension, to the patient's underlying risk factors for hearing loss, a combination of these factors, or to
1 INDICATIONS AND USAGE Sildenafil for Oral Suspension is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in adults to improve exercise ability and delay clinical worsening. The delay in clinical worsening was demonstrated when Sildenafil for Oral Suspension was added to background epoprostenol therapy [see Clinical Studies (14)].Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II–III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%).Limitation of Use: Adding sildenafil to bosentan therapy does not result in any beneficial effect on exercise capacity [see Clinical Studies (14)]. Sildenafil for Oral Suspension is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in adults to improve exercise ability and delay clinical worsening. The delay in clinical worsening was demonstrated when Sildenafil for Oral Suspension was added to background epoprostenol therapy [see Clinical Studies (14)]. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II–III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%).
Limitation of Use: Adding sildenafil to bosentan therapy does not result in any beneficial effect on exercise capacity [see Clinical Studies (14)]. 2 DOSAGE AND ADMINISTRATION 2.1 Sildenafil for Oral SuspensionThe recommended dose of Sildenafil for Oral Suspension is 5 mg or 20 mg three times a day. Administer Sildenafil for Oral Suspension doses 4–6 hours apart.In the clinical trial no greater efficacy was achieved with the use of higher doses. Treatment with doses higher than sildenafil white 20 mg three times a day is not recommended.2.3 Reconstitution of the Powder for Oral SuspensionNote: Reconstitute the contents of the bottle with a total volume of 90 mL (60 mL followed by 30 mL). Refer to the detailed instructions below.Tap the bottle to release the powder.Remove the cap.Accurately measure out 60 mL of water and pour the water into the bottle. other factors.Advise patients to seek prompt medical attention in the event of sudden decrease or loss of hearing
while taking PDE-5 inhibitors, including Sildenafil for Oral Suspension.5.7 Combination with other PDE-5 inhibitorsSildenafil is also marketed as VIAGRA®.
(Figure 1)Figure 1Replace the cap and shake the bottle vigorously for a minimum of 30 seconds. (Figure 2)Figure 2Remove the cap.Accurately measure out another 30 mL of water and add this to the bottle. You should always add a total of 90 mL of water irrespective of the dose prescribed. (Figure 3)Figure 3Replace the cap and shake the bottle vigorously for a minimum of 30 seconds. (Figure 4)Figure 4Remove the cap.Press the bottle adaptor into the neck of the bottle (as shown on Figure 5, below).
The adaptor is provided so that you can fill the oral syringe with medicine from the bottle. Replace the cap on the bottle.Figure 5Write the expiration date of the reconstituted oral suspension on the bottle label (the expiration date of the reconstituted oral suspension is 60 days from the date of reconstitution). The recommended dose of Sildenafil for Oral Suspension is 5 mg or 20 mg three times a day. Administer Sildenafil for Oral Suspension doses 4–6 hours apart. In the clinical trial no greater efficacy was achieved with the use of higher doses. The safety and efficacy of combinations of Sildenafil for Oral Suspension with VIAGRA or other PDE-5 inhibitors have not been studied.
Most, but not all, of these patients had underlying anatomic buy sildenafil uk or vascular risk factors for developing NAION, including but not necessarily limited to: low cup to disc ratio (“crowded disc”), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia and smoking. Based on published literature, the annual incidence of NAION is 2.5–11.8 cases per 100,000 males aged ≥50 per year in the general population.An observational case-crossover study evaluated the risk of NAION when PDE-5 inhibitor use, as a class, occurred immediately before NAION onset (within 5 half-lives), compared to PDE-5 inhibitor use in a prior time period. The results suggest an approximate 2-fold increase in the risk of NAION, with a risk estimate of 2.15 (95% CI 1.06, 4.34). A similar study reported a consistent result, with a risk estimate of 2.27 (95% CI 0.99, 5.20). Other risk factors for NAION, such as the presence of “crowded” optic disc, may have contributed to the occurrence of NAION in these studies.Neither the rare postmarketing reports, nor the association of PDE-5 inhibitor use and NAION in the observational studies, substantiate a causal relationship between PDE-5 inhibitor use and NAION [see Adverse Reactions (6.2].Advise patients to seek immediate medical attention in the event of a sudden loss of vision in one or both eyes while taking PDE-5 inhibitors, including Sildenafil for Oral Suspension. Inform patients taking Sildenafil for Oral Suspension not to take VIAGRA or other PDE-5 inhibitors.5.8 PriapismUse Sildenafil for Oral Suspension with caution in patients with anatomical deformation of
| Region | Estimated Market Size (2023) | Growth Rate | Key Players | Typical Uses Scope |
|---|---|---|---|---|
| North America | $150 million | 5% annually | Pfizer, Cipla, Teva | ED, pulmonary hypertension |
| Europe | $100 million | 4.5% annually | Bayer, Sun Pharma | Pulmonary hypertension, off-label uses |
| Asia-Pacific | $200 million | 7% annually | Cipla, Aurobindo, Zydus | Broader use, pediatric cases |
| Rest of World | $50 million | 3.5% annually | Various local manufacturers | Growing awareness and approval |
the penis (e.g., angulation, cavernosal fibrosis, or Peyronie's disease) or in patients who have conditions, which may predispose them to priapism (e.g., sickle cell anemia, multiple myeloma, or leukemia).
Treatment with doses higher than 20 mg three times a day is not recommended. Tap the bottle to release the powder. Accurately measure out 60 mL of water and pour the water into the bottle. Accurately measure out another 30 mL of water and add this to the bottle. Press the bottle adaptor into the neck of the bottle sildenafil 100 mg cost (as shown on Figure 5, below).
3 DOSAGE FORMS AND STRENGTHS Sildenafil for Oral SuspensionWhite to off-white powders containing 1.57 g of sildenafil citrate (equivalent to 1.12 g of sildenafil) in a bottle intended for reconstitution. A 2 mL oral syringe (with 0.5 mL and 2 mL dose markings) and a press-in bottle adaptor are also provided. White to off-white powders containing 1.57 g of sildenafil citrate (equivalent to 1.12 g of sildenafil) in a bottle intended for reconstitution. 4 CONTRAINDICATIONS Sildenafil for Oral Suspension is contraindicated in patients with:Concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension [see Warnings and Precautions (5.2)].Concomitant use of riociguat, a guanylate cyclase stimulator. PDE-5 inhibitors, including sildenafil, may potentiate the hypotensive effects of riociguat.Known hypersensitivity to sildenafil or any component of the tablet, injection, or oral suspension.